Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
37
AARD Quote, Financials, Valuation and Earnings
Last price:
$13.09
Seasonality move
:
--
Day range:
$13.00 - $13.63
52-week range:
$4.88 - $19.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.34x
Volume:
89.6K
Avg. volume:
236.3K
1-year change:
--
Market cap:
$285.8M
Revenue:
--
EPS (TTM):
-$2.25
Analysts' Opinion
-
Consensus RatingAardvark Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.70, Aardvark Therapeutics, Inc. has an estimated upside of 149.14% from its current price of $13.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $13.13.
Fair Value
-
According to the consensus of 9 analysts, Aardvark Therapeutics, Inc. has 149.14% upside to fair value with a price target of $32.70 per share.
AARD vs. S&P 500
-
Over the past 5 trading days, Aardvark Therapeutics, Inc. has underperformed the S&P 500 by -6.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aardvark Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aardvark Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Aardvark Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Aardvark Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aardvark Therapeutics, Inc. reported earnings per share of -$0.75.
Enterprise value:
160M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$26K
Return On Assets:
-40.71%
Net Income Margin (TTM):
--
Return On Equity:
-43.34%
Return On Invested Capital:
-43.07%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$26K | -$162K | -$26K | -$87K | -$10K | |
| Operating Income | -- | -$15.6M | -$53.5M | -$5.1M | -$17.7M | |
| EBITDA | -- | -$15.4M | -$53.6M | -$5M | -$17.7M | |
| Diluted EPS | -$0.10 | -$3.27 | -$2.25 | -$0.20 | -$0.75 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $82.7M | $129.2M | |
| Total Assets | -- | -- | -- | $83.7M | $133.2M | |
| Current Liabilities | -- | -- | -- | $2.6M | $10.7M | |
| Total Liabilities | -- | -- | -- | $3.2M | $10.9M | |
| Total Equity | -- | -- | -- | $80.6M | $122.4M | |
| Total Debt | -- | -- | -- | $545K | $116K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$48.7M | -- | -$18.5M | |
| Cash From Investing | -- | -- | -$85.9M | -- | $29.2M | |
| Cash From Financing | -- | -- | $91.5M | -- | $2.6M | |
| Free Cash Flow | -- | -- | -$48.8M | -- | -$18.5M | |
AARD
Sector
Market Cap
$285.8M
--
Price % of 52-Week High
67.03%
--
Dividend Yield
0%
--
Shareholder Yield
-31.71%
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$13.72
200-day SMA
Buy
Level
$11.22
Bollinger Bands (100)
Buy
Level
9.27 - 13.95
Chaikin Money Flow
Sell
Level
-303.2K
20-day SMA
Sell
Level
$13.50
Relative Strength Index (RSI14)
Buy
Level
51.09
ADX Line
Buy
Level
22.03
Williams %R
Buy
Level
-90.8373
50-day SMA
Buy
Level
$11.69
MACD (12, 26)
Buy
Level
0.56
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
3.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-3.1492)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (8.7525)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, AARD has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AARD average analyst price target in the past 3 months is $32.70.
-
Where Will Aardvark Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aardvark Therapeutics, Inc. share price will rise to $32.70 per share over the next 12 months.
-
What Do Analysts Say About Aardvark Therapeutics, Inc.?
Analysts are divided on their view about Aardvark Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aardvark Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is Aardvark Therapeutics, Inc.'s Price Target?
The price target for Aardvark Therapeutics, Inc. over the next 1-year time period is forecast to be $32.70 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AARD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aardvark Therapeutics, Inc. is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AARD?
You can purchase shares of Aardvark Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aardvark Therapeutics, Inc. shares.
-
What Is The Aardvark Therapeutics, Inc. Share Price Today?
Aardvark Therapeutics, Inc. was last trading at $13.09 per share. This represents the most recent stock quote for Aardvark Therapeutics, Inc.. Yesterday, Aardvark Therapeutics, Inc. closed at $13.13 per share.
-
How To Buy Aardvark Therapeutics, Inc. Stock Online?
In order to purchase Aardvark Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AARD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AARD
Sector
P/E ratio
--
--
PEG ratio
--
--
P/B ratio
2.34x
--
Price / LTM sales
--
--
Growth Metrics
AARD
Sector
Revenue growth
--
--
Earnings growth
-283.59%
--
Revenue (5-year growth)
--
--
Earnings forecast
-$0.83
--
Profitability
AARD
Sector
Profitability FY 2024
-$16K
--
Return on invested capital
-43.07%
--
Return on assets
-40.71%
--
Return on equity
-43.34%
--
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
12
Balance Sheet
AARD
Sector
Total cash
$126.4M
--
Short term investments
$12M
--
Total assets
$77.5M
--
Long term debt
$116K
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 7.96% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 2.39% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 9.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
